Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Virology ; 537: 149-156, 2019 11.
Article in English | MEDLINE | ID: mdl-31493653

ABSTRACT

Screening for human papillomavirus (HPV) integration into host cell chromosomes typically requires large amounts of time and reagents. We developed a rapid and sensitive assay based on exonuclease V (ExoV) and quantitative polymerase chain reaction (qPCR) to determine HPV genome configurations in cell lines and tissues. We established the assay using genomic DNA from cell lines known to harbor integrated or episomal HPV16. DNA was incubated with ExoV, which is specific for linear DNA, and the DNA fraction resistant to digestion was measured by qPCR. The percent of DNA resistant to ExoV digestion was calculated relative to undigested DNA for determination of episomal or integrated HPV16. The ExoV assay was accurate, capable of distinguishing episomal from integrated HPV16 in cell lines and tissues. Future applications of the ExoV assay may include screening of HPV genome configurations in the progression of HPV-associated cancers.


Subject(s)
DNA, Viral/analysis , Exodeoxyribonuclease V/metabolism , Human papillomavirus 16/genetics , Plasmids , Proviruses/genetics , Real-Time Polymerase Chain Reaction/methods , Virus Integration , Cells, Cultured , DNA, Viral/genetics , Human papillomavirus 16/growth & development , Humans
2.
J Virol ; 93(2)2019 01 15.
Article in English | MEDLINE | ID: mdl-30381489

ABSTRACT

Epstein-Barr virus (EBV) is implicated in the pathogenesis of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OSCC). EBV-associated cancers harbor a latent EBV infection characterized by a lack of viral replication and the expression of viral oncogenes. Cellular changes promoted by HPV are comparable to those shown to facilitate EBV latency, though whether HPV-positive cells support a latent EBV infection has not been demonstrated. Using a model of direct EBV infection into HPV16-immortalized tonsillar cells grown in organotypic raft culture, we showed robust EBV replication in HPV-negative rafts but little to no replication in HPV-immortalized rafts. The reduced EBV replication was independent of immortalization, as human telomerase-immortalized normal oral keratinocytes supported robust EBV replication. Furthermore, we observed reduced EBV lytic gene expression and increased expression of EBER1, a noncoding RNA highly expressed in latently infected cells, in the presence of HPV. The use of human foreskin keratinocyte rafts expressing the HPV16 E6 and/or E7 oncogene(s) (HPV E6 and E7 rafts) showed that E7 was sufficient to reduce EBV replication. EBV replication is dependent upon epithelial differentiation and the differentiation-dependent expression of the transcription factors KLF4 and PRDM1. While KLF4 and PRDM1 levels were unaltered, the expression levels of KLF4 transcriptional targets, including late differentiation markers, were reduced in HPV E6 and E7 rafts compared to their levels in parental rafts. However, the HPV E7-mediated block in EBV replication correlated with delayed expression of early differentiation markers. Overall, this study reveals an HPV16-mediated block in EBV replication, through E7, that may facilitate EBV latency and long-term persistence in the tumor context.IMPORTANCE Using a model examining the establishment of EBV infection in HPV-immortalized tissues, we showed an HPV-induced interruption of the normal EBV life cycle reminiscent of a latent EBV infection. Our data support the notion that a persistent EBV epithelial infection depends upon preexisting cellular alterations and suggest the ability of HPV to promote such changes. More importantly, these findings introduce a model for how EBV coinfection may influence HPV-positive (HPV-pos) OSCC pathogenesis. Latently EBV-infected epithelial cells, as well as other EBV-associated head-and-neck carcinomas, exhibit oncogenic phenotypes commonly seen in HPV-pos OSCC. Therefore, an HPV-induced shift in the EBV life cycle toward latency would not only facilitate EBV persistence but also provide additional viral oncogene expression, which can contribute to the rapid progression of HPV-pos OSCC. These findings provide a step toward defining a role for EBV as a cofactor in HPV-positive oropharyngeal tumors.


Subject(s)
Epithelial Cells/virology , Herpesvirus 4, Human/physiology , Human papillomavirus 16/metabolism , Keratinocytes/cytology , Oncogene Proteins, Viral/metabolism , Papillomavirus E7 Proteins/metabolism , Repressor Proteins/metabolism , Animals , Cell Differentiation , Cells, Cultured , Coculture Techniques , Epithelial Cells/cytology , Foreskin/cytology , Human papillomavirus 16/physiology , Humans , Keratinocytes/virology , Kruppel-Like Factor 4 , Male , Mice , NIH 3T3 Cells , Palatine Tonsil/cytology , Palatine Tonsil/virology , Virus Latency , Virus Replication
3.
Oral Dis ; 24(4): 497-508, 2018 May.
Article in English | MEDLINE | ID: mdl-28190296

ABSTRACT

Epstein-Barr virus (EBV) is a ubiquitous gamma-herpesvirus that establishes a lifelong persistent infection in the oral cavity and is intermittently shed in the saliva. EBV exhibits a biphasic life cycle, supported by its dual tropism for B lymphocytes and epithelial cells, which allows the virus to be transmitted within oral lymphoid tissues. While infection is often benign, EBV is associated with a number of lymphomas and carcinomas that arise in the oral cavity and at other anatomical sites. Incomplete association of EBV in cancer has questioned if EBV is merely a passenger or a driver of the tumorigenic process. However, the ability of EBV to immortalize B cells and its prevalence in a subset of cancers has implicated EBV as a carcinogenic cofactor in cellular contexts where the viral life cycle is altered. In many cases, EBV likely acts as an agent of tumor progression rather than tumor initiation, conferring malignant phenotypes observed in EBV-positive cancers. Given that the oral cavity serves as the main site of EBV residence and transmission, here we review the prevalence of EBV in oral malignancies and the mechanisms by which EBV acts as an agent of tumor progression.


Subject(s)
Carcinoma, Squamous Cell/virology , Epstein-Barr Virus Infections/complications , Herpesvirus 4, Human , Life Cycle Stages , Lymphoma/virology , Mouth Neoplasms/virology , Herpesvirus 4, Human/growth & development , Humans , Leukoplakia, Hairy/virology , Salivary Gland Neoplasms/virology
4.
Virus Res ; 231: 139-147, 2017 03 02.
Article in English | MEDLINE | ID: mdl-27826043

ABSTRACT

The etiological role of human papillomavirus (HPV) in anogenital tract and head and neck cancers is well established. However, only a low percentage of HPV-positive women develop cancer, indicating that HPV is necessary but not sufficient in carcinogenesis. Several biological and environmental cofactors have been implicated in the development of HPV-associated carcinoma that include immune status, hormonal changes, parity, dietary habits, tobacco usage, and co-infection with other sexually transmissible agents. Such cofactors likely contribute to HPV persistent infection through diverse mechanisms related to immune control, efficiency of HPV infection, and influences on tumor initiation and progression. Conversely, HPV co-infection with other factors may also harbor anti-tumor effects. Here, we review epidemiological and experimental studies investigating human immunodeficiency virus (HIV), herpes simplex virus (HSV) 1 and 2, human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), BK virus (BKV), JC virus (JCV), and adeno-associated virus (AAV) as viral cofactors in or therapeutic factors against the development of genital and oral HPV-associated carcinomas.


Subject(s)
Anus Neoplasms/virology , Genital Neoplasms, Female/virology , Head and Neck Neoplasms/virology , Papillomaviridae/pathogenicity , Papillomavirus Infections/virology , Anus Neoplasms/genetics , Anus Neoplasms/immunology , Anus Neoplasms/pathology , BK Virus/genetics , BK Virus/growth & development , BK Virus/pathogenicity , Carcinogenesis/genetics , Carcinogenesis/immunology , Carcinogenesis/pathology , Coinfection , Cytomegalovirus/genetics , Cytomegalovirus/growth & development , Cytomegalovirus/pathogenicity , Dependovirus/genetics , Dependovirus/growth & development , Dependovirus/pathogenicity , Female , Genital Neoplasms, Female/genetics , Genital Neoplasms, Female/immunology , Genital Neoplasms, Female/pathology , HIV/genetics , HIV/growth & development , HIV/pathogenicity , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/immunology , Head and Neck Neoplasms/pathology , Herpesvirus 1, Human/genetics , Herpesvirus 1, Human/growth & development , Herpesvirus 1, Human/pathogenicity , Herpesvirus 2, Human/genetics , Herpesvirus 2, Human/growth & development , Herpesvirus 2, Human/pathogenicity , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/growth & development , Herpesvirus 4, Human/pathogenicity , Humans , JC Virus/genetics , JC Virus/growth & development , JC Virus/pathogenicity , Papillomaviridae/genetics , Papillomaviridae/growth & development , Papillomavirus Infections/genetics , Papillomavirus Infections/immunology , Papillomavirus Infections/pathology , Protective Factors , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL